Debiopharm announced that the Food and Drug Administration (FDA) has granted Fast Track designation for Debio 1450, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Debio 1450 is an oral/IV FabI inhibitor active against all Staphylococcus species, including methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA). The specificity of Debio 1450 is expected to preserve the human gut microbiota leading to minimal antibiotic-associated side effects.
In September 2014, Debio 1450 was designated a Qualified Infectious Disease Product (QIDP) for ABSSSI.
For more information visit Debiopharm.com.